Literature DB >> 21361792

Effects of interferons α/β on the proliferation of human micro- and macrovascular endothelial cells.

Joris Erdmann1, Giovanni Vitale, Peter M van Koetsveld, Ed Croze, Diane M Sprij-Mooij, Leo J Hofland, Casper H J van Eijck.   

Abstract

Synthetic interferons (IFNs) are used in the treatment of several types of cancer. In addition to an antitumor effect, IFNs show antiangiogenic activity. The aim of this study was to investigate the effects of IFN-α and IFN-β on human micro- and macrovascular endothelial cells in vitro [human micro vascular lung endothelial cells (HMVEC-L) and human umbilical cord endothelial cells (HUVEC)]. By immunohistochemical staining and quantitative reverse transcriptase (RT)-polymerase chain reaction, we studied expression of type I IFN receptors. We evaluated the effects of IFN-α and IFN-β on the proliferation (DNA content), apoptosis (DNA fragmentation by enzyme-linked immunosorbent assay), and cell cycle distribution (flow-cytometric analysis) of endothelial cells. HUVEC and HMVEC-L cells show comparable expression level of the distinct IFN receptor subtypes. Proliferation of HMVEC-L and HUVEC was inhibited by IFN-β (the half maximal inhibitory concentration [IC(50)] = 60 and 90 IU/mL, respectively), but not by IFN-α at a dose up to 1,000 IU/mL. An interesting and unexpected observation was an inhibition of apoptosis by IFN-β. After 72 h of treatment with IFN-β. Cell cycle inhibition occurs in late S-phase in both cell lines. In conclusion, only IFN-β, not IFN-α (10-1,000 IU/mL), has an inhibitory activity on endothelial cell proliferation. Surprisingly, apoptosis was decreased by IFN treatment, whereas inhibition of proliferation is caused by cell cycle arrest in late S-phase.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21361792     DOI: 10.1089/jir.2009.0103

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  6 in total

1.  Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome.

Authors:  Robert C Grenn; Srilakshmi Yalavarthi; Alex A Gandhi; Nayef M Kazzaz; Carlos Núñez-Álvarez; Diego Hernández-Ramírez; Antonio R Cabral; W Joseph McCune; Paula L Bockenstedt; Jason S Knight
Journal:  Ann Rheum Dis       Date:  2016-07-18       Impact factor: 19.103

2.  Antitumor activity of interferon-β1a in hormone refractory prostate cancer with neuroendocrine differentiation.

Authors:  A Dicitore; E S Grassi; M O Borghi; G Gelmini; M C Cantone; G Gaudenzi; L Persani; M Caraglia; G Vitale
Journal:  J Endocrinol Invest       Date:  2017-03-01       Impact factor: 4.256

3.  Expression, regulation, and function of atypical chemerin receptor CCRL2 on endothelial cells.

Authors:  Justin Monnier; Susanna Lewén; Edward O'Hara; Kexin Huang; Hua Tu; Eugene C Butcher; Brian A Zabel
Journal:  J Immunol       Date:  2012-06-13       Impact factor: 5.422

Review 4.  Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer.

Authors:  Angélica Ortiz; Serge Y Fuchs
Journal:  Cytokine       Date:  2016-01-25       Impact factor: 3.861

5.  The effect of type 1 IFN on human aortic endothelial cell function in vitro: relevance to systemic lupus erythematosus.

Authors:  John A Reynolds; David W Ray; Leo A H Zeef; Terence O'Neill; Ian N Bruce; M Yvonne Alexander
Journal:  J Interferon Cytokine Res       Date:  2014-01-20       Impact factor: 2.607

Review 6.  Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.

Authors:  Ruan F V Medrano; Aline Hunger; Samir Andrade Mendonça; José Alexandre M Barbuto; Bryan E Strauss
Journal:  Oncotarget       Date:  2017-07-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.